Squamous cell carcinoma of cervical lymph nodes from an unknown primary site: The impact of neck dissection

Journal of Cancer Research and Therapeutics

Volumn 11, Issue , 2015, Pages C161-C167

  Lou, Jianlin ^a   Wang, Shengye ^a   Wang, Kejing ^a   Chen, Chao ^a   Zhao, Jianqiang ^a   Guo, Liang ^a  

^a ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

Carcinoma; lymphatic metastasis; neoplasms; radical neck dissection; squamous cell; unknown primary

Indexed keywords

CISPLATIN; FLUOROURACIL; NIMOTUZUMAB;

ADULT; ARTICLE; CANCER OF UNKNOWN PRIMARY SITE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CERVICAL LYMPH NODE; FEMALE; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NECK DISSECTION; NECK METASTASIS; OVERALL SURVIVAL; PROPORTIONAL HAZARDS MODEL; SQUAMOUS CELL CARCINOMA; TREATMENT FAILURE; UNIVARIATE ANALYSIS; AGED; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL FEATURE; COHORT ANALYSIS; DISTANT METASTASIS; FOLLOW UP; LYMPH NODE METASTASIS; MEDIAN SURVIVAL TIME; PRIMARY TUMOR; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA OF CERVICAL LYMPH NODE FROM AN UNKNOWN PRIMARY SITE; SURVIVAL RATE; ADVERSE EFFECTS; CANCER GRADING; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; LYMPH NODE; METASTASIS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOPLASMS, UNKNOWN PRIMARY; PATHOLOGY; SECONDARY; TREATMENT OUTCOME; TUMOR RECURRENCE; YOUNG ADULT;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODES; MALE; MIDDLE AGED; NECK DISSECTION; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, UNKNOWN PRIMARY; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84946012843     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.168178     Document Type: Article

References (20)

1. Strojan P, Anicin A. Combined surgery and postoperative radiotherapy for cervical lymph node metastases from an unknown primary tumour. Radiother Oncol 1998; 49: 33-40.
2. Regelink G, Brouwer J, de Bree R, Pruim J, van der Laan BF, Vaalburg W, et al. Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities. Eur J Nucl Med Mol Imaging 2002; 29: 1024-30.
3. Issing WJ, Taleban B, Tauber S. Diagnosis and management of carcinoma of unknown primary in the head and neck. Eur Arch Otorhinolaryngol 2003; 260: 436-43.
4. Beldì D, Jereczek-Fossa BA, D'Onofrio A, Gambaro G, Fiore MR, Pia F, et al. Role of radiotherapy in the treatment of cervical lymph node metastases from an unknown primary site: retrospective analysis of 113 patients. Int J Radiat Oncol Biol Phys 2007; 69: 1051-8.
5. Strojan P, Ferlito A, Medina JE, Woolgar JA, Rinaldo A, Robbins KT, et al. Contemporary management of lymph node metastases from an unknown primary to the neck: I. A review of diagnostic approaches. Head Neck 2013; 35: 123-32.
6. Strojan P, Ferlito A, Langendijk JA, Corry J, Woolgar JA, Rinaldo A, et al. Contemporary management of lymph node metastases from an unknown primary to the neck: II. a review of therapeutic options. Head Neck 2013; 35: 286-93.
7. Wang CF, Zhao P. Clinical research of cancers of unknown primary deserves special emphasis. Zhonghua Yi Xue Za Zhi 2006; 86: 1801-3.
8. Cerezo L, Raboso E, Ballesteros AI. Unknown primary cancer of the head and neck: a multidisciplinary approach. Clin Transl Oncol 2011; 13: 88-97.
9. Zhuang SM, Wu XF, Li JJ, Zhang GH. Management of lymph node metastases from an unknown primary site to the head and neck (Review). Mol Clin Oncol 2014; 2: 917-922.
10. Pavlidis N, Pentheroudakis G, Plataniotis G. Cervical lymph node metastases of squamous cell carcinoma from an unknown primary site: a favourable prognosis subset of patients with CUP. Clin Transl Oncol 2009; 11: 340-8.
11. Schmidt T, Ulrich A. Surgical options in cancer of unknown primary (CUP). Radiologe 2014; 54: 140-4.
12. Patel RS, Clark J, Wyten R, Gao K, O'Brien CJ. Squamous cell carcinoma from an unknown head and neck primary site: a 'selective treatment' approach. Arch Otolaryngol Head Neck Surg 2007; 133: 1282-7.
13. Shoushtari A, Saylor D, Kerr KL, Sheng K, Thomas C, Jameson M, et al. Outcomes of patients with head-and-neck cancer of unknown primary origin treated with intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2011; 81: e83-91.
14. Lu X, Hu C, Ji Q, Shen C, Feng Y. Squamous cell carcinoma metastatic to cervical lymph nodes from an unknown primary site: the impact of radiotherapy. Tumori 2009; 95: 185-90.
15. Chen AM, Farwell DG, Lau DH, Li BQ, Luu Q, Donald PJ. Radiation therapy in the management of head-and-neck cancer of unknown primary origin: how does the addition of concurrent chemotherapy affect the therapeutic ratio? Int J Radiat Oncol Biol Phys 2011; 81: 346-52.
16. Fakhrian K, Thamm R, Knapp S, Molls M, Pigorsch S, Haller B, et al. Radio (chemo) therapy in the management of squamous cell carcinoma of cervical lymph nodes from an unknown primary site. A retrospective analysis. Strahlenther Onkol 2012; 188: 56-61.
17. Hamoir M, Troussier I, Machiels JP, Reychler H, Schmitz S, Thariat J, et al. Lymph node metastases from squamous cell carcinoma of unknown primary site. Is it time to change of paradigm? Bull Cancer 2014; 101: 455-60.
18. Dragan AD, Nixon IJ, Guerrero-Urbano MT, Oakley R, Jeannon JP, Simo R. Selective neck dissection as a therapeutic option in management of squamous cell carcinoma of unknown primary. Eur Arch Otorhinolaryngol 2014; 271: 1249-56.
19. Aslani M, Sultanem K, Voung T, Hier M, Niazi T, Shenouda G. Metastatic carcinoma to the cervical nodes from an unknown head and neck primary site: Is there a need for neck dissection? Head Neck 2007; 29: 585-90.
20. Eldeeb H, Hamed RH. Squamous cell carcinoma metastatic to cervical lymph nodes from unknown primary origin: the impact of chemoradiotherapy. Chin J Cancer 2012; 31: 484-90.